Co-Diagnostics, Inc. technology to be used in FDA cleared self-collected COVID-19 saliva test


SALT LAKE CITY, Aug 3, 2020 / PRNewswire / – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic assays, today announced that its partner, Clinical Reference Laboratory (CRL), has received approval for use of emergency response for CRL Rapid Response ™, a saliva-based COVID-19 test that can be self-administered at home, work, or other setting, then tested using patented CoPrimer ™ technology. Co-Diagnostics.According to CRL’s announcement, Co-Diagnostics technology stimulates the higher sensitivity and specificity of the self-administered CRL Rapid Response assay. CRL is one of the largest private clinical trial laboratories in the United States, with dedicated facilities North America and L’Europe .

“We believe that CRL’s selection of the Co-Diagnostics platform, and their successful emergency use clearance from the FDA, speaks volumes about the quality, sensitivity and specificity of our primer technology and of CoPrimer probe, ”noted Dwight Egan, CEO of Co-Diagnostics. “Co-Diagnostics is happy to be part of a testing initiative with so much potential to help people return to work, school and normal lives as quickly and safely as possible.

The Logix Smart COVID-19 CE marked and FDA EUA Co-Diagnostics test is currently available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA), and is authorized for use in the diagnosis of SARS-CoV-2, virus that causes COVID-19 in the United States and many other countries.

About Co-Diagnostics, Inc .:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets new advanced diagnostic technology. The Company’s technology is used for tests designed using the detection and / or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific assays to locate genetic markers for use in industries other than infectious diseases and authorize the use of these assays to specific customers.

Forward-looking statements:
This press release contains forward-looking statements. Forward-looking statements may be identified by words such as “believes”, “expects”, “believes”, “intends”, “may”, “plans”, “will” and similar expressions, or the negative of these words. . These forward-looking statements are based on facts and conditions as they exist at the time these statements are made and forecasts as to future facts and conditions. Forward-looking statements contained in this press release include statements regarding (i) use of the financing proceeds, (ii) expansion of product distribution, (iii) acceleration of liquid biopsy and SNP detection initiatives , (iv) the use of the company’s liquid biopsy tests by laboratories, (v) the capital resources and lead needed to advance the company’s products and markets, (vi) increased sales short-term, (vii) flexibility in managing the company’s balance sheet, (viii) anticipation of business expansion, and (ix) research benefits and global accessibility of CoPrimer technology and its scientific and economic benefits. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by these forward-looking statements. Readers of this press release are cautioned not to place undue reliance on forward-looking statements. The Company assumes no obligation to update any forward-looking statements relating to the matters discussed in this press release, except to the extent required by applicable securities laws.

SOURCE Co-diagnostic

Related links



Please enter your comment!
Please enter your name here